Rajendra Wudayagiri

TL;DR: The present review explains the currently available biomarkers for cervical cancer diagnosis and prognosis and strategies for the development of biomarkers based on cellular and molecular approaches such as DNA, protein and other metabolic markers with suitable clinical examples.

TL;DR: The docking studies demonstrate that compound 27, 28, 29 and 30 have good dock score and binding affinities with various therapeutic targets in cancer cell proliferation and these compounds have shown acceptable correlation with bioassay results in the regression plots generated in 2D QSAR models.

TL;DR: In vitro results demonstrate that compounds 22, 27, 36 and 40 have pivotal anticancer activity; among these, compounds 22 and 27 have significant cytotoxic activity in all three cell lines; the in silico docking studies reveal that compounds22, 27 and 36 have good dock scores, binding affinities and binding energies towards human epidermal growth factor receptor 2.

TL;DR: Assessment of the probiotic nature of Lactobacillus in preventing cervical pathogens by studying the effectiveness of antimicrobial activity against vaginal pathogens.

TL;DR: Among the synthesized bioactive molecules, 4a, 4d, 4g, and 4h exhibited promising antioxidant activity compared with the standard drug Ascorbic acid, and molecular docking studies were performed against Aromatase enzyme for four compounds to support the biological results of the compounds.